Abstract
Integrins α1β1 and α2β1 are highly expressed on the microvascular endothelial cells, and blocking of their adhesive properties significantly reduced the VEGF-driven neovascularization ratio and tumor growth in animal models. Hence, inhibitors of the α1β1 and α2β1 integrins, alone or in combination with antagonists of other integrins involved in angiogenesis (eg. αvβ3, αvβ5, and α6β4), may prove benefitial in the control of tumor neovascularization. Viperidae snakes have developed in their venoms an efficient arsenal of integrin receptor antagonists. KTS- (obtustatin, viperistatin, lebestatin) and RTS- (jerdostatin) disintegrins represent viper venom peptides that specifically block the interaction of the α1β1 integrin with collagens IV and I in vitro and angiogenesis in vivo. The possible therapeutic approach towards tumor neovascularization by targeting the α5β1, αvβ5 and αvβ3 integrins with RGD-bearing disintegrins has been explored in a number of laboratories. Here we discuss structure-function correlations of the novel group of specific (K/R)TS-disintegrins targeting the α1β1 integrin.
Keywords: extracellular matrix, integrin inhibitor, synthetic RGD peptides, obtustatin, viperistatin
Current Pharmaceutical Design
Title: KTS and RTS-Disintegrins: Anti-Angiogenic Viper Venom Peptides Specifically Targeting the α1β 1 Integrin
Volume: 13 Issue: 28
Author(s): Juan J. Calvete, Cezary Marcinkiewicz and Libia Sanz
Affiliation:
Keywords: extracellular matrix, integrin inhibitor, synthetic RGD peptides, obtustatin, viperistatin
Abstract: Integrins α1β1 and α2β1 are highly expressed on the microvascular endothelial cells, and blocking of their adhesive properties significantly reduced the VEGF-driven neovascularization ratio and tumor growth in animal models. Hence, inhibitors of the α1β1 and α2β1 integrins, alone or in combination with antagonists of other integrins involved in angiogenesis (eg. αvβ3, αvβ5, and α6β4), may prove benefitial in the control of tumor neovascularization. Viperidae snakes have developed in their venoms an efficient arsenal of integrin receptor antagonists. KTS- (obtustatin, viperistatin, lebestatin) and RTS- (jerdostatin) disintegrins represent viper venom peptides that specifically block the interaction of the α1β1 integrin with collagens IV and I in vitro and angiogenesis in vivo. The possible therapeutic approach towards tumor neovascularization by targeting the α5β1, αvβ5 and αvβ3 integrins with RGD-bearing disintegrins has been explored in a number of laboratories. Here we discuss structure-function correlations of the novel group of specific (K/R)TS-disintegrins targeting the α1β1 integrin.
Export Options
About this article
Cite this article as:
Calvete J. Juan, Marcinkiewicz Cezary and Sanz Libia, KTS and RTS-Disintegrins: Anti-Angiogenic Viper Venom Peptides Specifically Targeting the α1β 1 Integrin, Current Pharmaceutical Design 2007; 13 (28) . https://dx.doi.org/10.2174/138161207782023766
DOI https://dx.doi.org/10.2174/138161207782023766 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticoagulation in Patients with Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Nanofiber Scaffolds for Treatment of Spinal Cord Injury
Current Medicinal Chemistry Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update
Recent Patents on Cardiovascular Drug Discovery New-Onset Hyperglycemia and Acute Coronary Syndrome: A Systematic Overview and Meta-Analysis
Current Diabetes Reviews Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy Innovative Strategy in Treating Angina Pectoris with Chinese Patent Medicines by Promoting Blood Circulation and Removing Blood Stasis: Experience from Combination Therapy in Chinese Medicine
Current Vascular Pharmacology Circulating Biomarkers Determining Inflammation in Atherosclerosis Progression
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Nitric Oxide Pathway as New Drug Targets for Refractory Hypertension
Current Pharmaceutical Design Role of Antioxidants in Redox Regulation of Diabetic Cardiovascular Complications
Current Pharmaceutical Biotechnology Hydrogen Gas Therapy: From Preclinical Studies to Clinical Trials
Current Pharmaceutical Design The Long Way to Objectify Organ Damage Related to Cocaine Abuse: Oxidative Stress is the Main Culprit
Mini-Reviews in Organic Chemistry Nutritional Supplements Modulating Metabolic Syndrome Risk Factors and the Prevention of Cardiovascular Disease
Current Nutrition & Food Science Sex Differences and Emerging New Risk Factors for Atherosclerosis and Its Thrombotic Complications
Current Pharmaceutical Design Barriers to Risk Stratification Accuracy in Ischemic Heart Disease in Women: The Role of Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design